Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Non-Alcoholic Fatty Liver Disease (NAFLD)
NCT02457286Phase 1Withdrawn
- Sponsor
- Northwell Health
- Start
- Jun 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of metformin in non-alcoholic fatty liver disease (NAFLD), sponsored by Northwell Health. Primary endpoint: Alanine Aminotransferase at 12 months. Planned start Jun 2015; status: withdrawn.
02
Drugs
metformin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02457286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02457286.